ESMO 2018 Erlotinib improves progressionfree survival in early mutated nonsmall cell lung cancer

ESMO 2018: Erlotinib improves progression-free survival in early mutated non-small cell lung cancer

08:07 EDT 21 Oct 2018 | ecancermedicalscience

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer (NSCLC), shows a randomised study comparing erlotinib with gemcitabine plus...

More From BioPortfolio on "ESMO 2018: Erlotinib improves progression-free survival in early mutated non-small cell lung cancer"